NCT07561333 Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee Arthroplasty
| NCT ID | NCT07561333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hitit University |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2025-10-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Total knee arthroplasty (TKA) is associated with severe postoperative pain that delays mobilization, prolongs hospital stay, and reduces patient satisfaction. Regional analgesia techniques have gained prominence due to their opioid-sparing effects and favorable complication profiles compared to general anesthesia. While adductor canal block (ACB) effectively manages anterior knee pain with preserved motor function, posterior knee pain remains a challenge. IPACK (Infiltration between the Popliteal Artery and Capsule of the Knee) and the Biceps Femoris Short Head (BiFeS) block are techniques targeting posterior capsule innervation without causing motor block.This prospective study aims to compare the postoperative analgesic efficacy of ultrasound-guided ACB+IPACK versus ACB+BiFeS block combinations in patients undergoing TKA under spinal anesthesia. Patients (ASA I-III, age 18-80, BMI ≤35) will be randomized into two groups (n=39 each). Primary outcomes include NRS pain scores at rest and on movement, and opioid consumption at 0, 1, 3, 6, 12, 18, and 24 hours postoperatively. Secondary outcomes include time to first mobilization, motor block incidence, quadriceps muscle strength assessment, PONV, and quality of recovery (QoR-15).
Eligibility Criteria
Inclusion Criteria: * Scheduled for primary total knee arthroplasty surgery * ASA physical status classification I-III * Hemodynamically stable * Age ≥ 18 years and ≤ 80 years * BMI ≤ 35 kg/m² * Signed written informed consent form Exclusion Criteria: * Revision total knee arthroplasty surgery * Simultaneous bilateral total knee arthroplasty * BMI \> 40 kg/m² * ASA physical status classification 4-5 * Inability to perform NRS pain scoring * Known allergy to local anesthetics * Pregnancy or breastfeeding * Age \< 18 or \> 80 years * Uncontrolled anxiety disorder * Alcohol or drug dependency * Neuromuscular disease or peripheral nerve disease * High-dose opioid use within 3 days prior to surgery * Widespread chronic pain syndrome * Diabetes mellitus * Hepatic or renal insufficiency * Coagulation disorders * Current use of anticoagulant medications * Infection at the peripheral nerve block needle insertion site * Refusal to participate in the study
Contact & Investigator
Guvenc DOGAN, MD
STUDY CHAIR
Hitit University
Frequently Asked Questions
Who can join the NCT07561333 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07561333 currently recruiting?
Yes, NCT07561333 is actively recruiting participants. Contact the research team at merveyagiz-1@hotmail.com for enrollment information.
Where is the NCT07561333 trial being conducted?
This trial is being conducted at Çorum, Turkey (Türkiye).
Who is sponsoring the NCT07561333 clinical trial?
NCT07561333 is sponsored by Hitit University. The principal investigator is Guvenc DOGAN, MD at Hitit University. The trial plans to enroll 78 participants.